Metal-Based Drugs [38] H. Kook, K. M. Kim, S. H. Choi et al., “Life-threatening carboplatin hypersensitivity during conditioning for autol- ogous PBSC transplantation: successful rechallenge after desensitization,” Bone Marrow Transplantation, vol. 21, no. 7, pp. 727–729, 1998. [39] S. Sliesoraitis and P. J. Chikhale, “Carboplatin hypersensitiv- ity,” International Journal of Gynecological Cancer, vol. 15, no. 1, pp. 13–18, 2005. [40] H. Sugimoto, T. Iwamoto, Y. Murashima, T. Tabata, N. Sagawa, and M. Okuda, “Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers,” Cancer Chemotherapy and Pharmacology, 2010. In press. [41] A. V. Hoekstra, J. A. Hurteau, C. V. Kirschner, and G. C. Rodriguez, “The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer,” Gynecologic Oncology, vol. 115, no. 3, pp. 377–381, 2009. [42] J. S. Morgan, M. Adams, and M. D. Mason, “Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma,” European Journal of Cancer A, vol. 30, no. 8, pp. 1205–1206, 1994. [43] C. Koren, R. Yerushalmi, A. Katz, H. Malik, A. Sulkes, and E. Fenig, “Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy,” Amer- ican Journal of Clinical Oncology, vol. 25, no. 6, pp. 625–626, 2002. [44] M. A. Bautista, W. T. Stevens, C.-S. Chen, B. R. Curtis, R. H. Aster, and C.-T. Hsueh, “Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature,” Journal of Hematology and Oncology, vol. 3, article 12, 2010. [45] Y. Shibata, H. Ariyama, E. Baba et al., “Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan,” International Journal of Clinical Oncology, vol. 14, no. 5, pp. 397–401, 2009. [46] B. H. Kim, T. Bradley, J. Tai, and D. R. Budman, “Hypersen- sitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review,” Oncology, vol. 76, no. 4, pp. 231–238, 2009. [47] A. A. Shlebak, P. I. Clark, and J. A. Green, “Hypersensitivity and cross-reactivity to cisplatin and analogues,” Cancer Chemotherapy and Pharmacology, vol. 35, no. 4, pp. 349–351, 1995. [48] C. Tournigand, F. Maindrault-Goebel, C. Louvet, A. de Gramont, and M. Krulik, “Severe anaphylactic reactions to oxaliplatin,” European Journal of Cancer, vol. 34, no. 8, pp. 1297–1298, 1998. [49] J. Medioni, M. A. Coulon, J. F. Morere, F. Hennebelle, S. Piperno-Neumann, and J. L. Breau, “Anaphylaxis after oxaliplatin,” Annals of Oncology, vol. 10, no. 5, p. 610, 1999. [50] A. Abe, H. Ikawa, and S. Ikawa, “Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer,” Journal of Medical Investigation, vol. 57, no. 1-2, pp. 163–167, 2010. [51] R. Gomez, P. Harter, H.-J. L u¨ck et al., “Carboplatin hyper- sensitivity does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single- center study,” International Journal of Gynecological Cancer, vol. 19, no. 7, pp. 1284–1287, 2009. [52] P. E. Hesterberg, A. Banerji, E. Oren et al., “Risk stratiﬁcation for desensitization of patients with carboplatin hypersen- sitivity: clinical presentation and management,” Journal of 9 Allergy and Clinical Immunology, vol. 123, no. 6, pp. 1262– 1267, 2009. [53] M. C. Castells, N. M. Tennant, D. E. Sloane et al., “Hyper- sensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases,” Journal of Allergy and Clinical Immunology, vol. 122, no. 3, pp. 574–580, 2008. [54] R. Conﬁno-Cohen, A. Fishman, M. Altaras, and A. Gold- berg, “Successful carboplatin desensitization in patients with proven carboplatin allergy,” Cancer, vol. 104, no. 3, pp. 640– 643, 2005. [55] C.-W. Lee, U. A. Matulonis, and M. C. Castells, “Rapid inpa- tient/outpatient desensitization for chemotherapy hypersen- sitivity: standard protocol eﬀective in 57 patients for 255 courses,” Gynecologic Oncology, vol. 99, no. 2, pp. 393–399, 2005. [56] M. Markman, F. Hsieh, K. Zanotti et al., “Initial experience with a novel desensitization strategy for carboplatin- associated hypersensitivity reactions: carboplatin- hypersensitivity reactions,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 1, pp. 25–28, 2004. [57] R. Jones, M. Ryan, and M. Friedlander, “Carboplatin hyper- sensitivity reactions: re-treatment with cisplatin desensitisa- tion,” Gynecologic Oncology, vol. 89, no. 1, pp. 112–115, 2003. [58] E. I. Syrigou, E. M. Karapanagiotou, C. V. Alamara, P. G. Boura, M. W. Saif, and K. N. Syrigos, “Hypersensitivity reactions to oxaliplatin: a retrospective study and the devel- opment of a desensitization protocol,” Clinical Colorectal Cancer, vol. 8, no. 2, pp. 106–109, 2009. [59] H. Nozawa, Y. Muto, and Y. Yamada, “Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer,” Clinical Therapeutics, vol. 30, no. 6, pp. 1160–1165, 2008. [60] S. H. Wrzesinski, M. L. McGurk, C. T. Donovan, T. M. Ferencz, and M. W. Saif, “Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate,” Anti-Cancer Drugs, vol. 18, no. 6, pp. 721–724, 2007. [61] D. A. Edmondson, B. J. Gruling, A. M. Urmanski, S. J. Wong, and M. B. Levy, “Oxaliplatin hypersensitivity: case report and successful repeat desensitization,” American Journal of Therapeutics, vol. 14, no. 1, pp. 116–118, 2007. [62] T. Herrero, P. Tornero, S. Infante et al., “Diagnosis and management of hypersensitivity reactions caused by oxali- platin,” Journal of Investigational Allergology and Clinical Immunology, vol. 16, no. 5, pp. 327–330, 2006. [63] L. Mis, N. H. Fernando, H. I. Hurwitz, and M. A. Morse, “Successful desensitization to oxaliplatin,” Annals of Pharma- cotherapy, vol. 39, no. 5, pp. 966–969, 2005. [64] K.-H. Lim, M.-J. Huang, H.-C. Lin et al., “Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule,” Anti-Cancer Drugs, vol. 15, no. 6, pp. 605–607, 2004. [65] D. Gammon, P. Bhargava, and M. J. McCormick, “Hyper- sensitivity reactions to oxaliplatin and the application of a desensitization protocol,” Oncologist, vol. 9, no. 5, pp. 546– 549, 2004. [66] B. Sch u¨ll, G. V. Kornek, and W. Scheithauer, “Idiosyncratic reaction after oxaliplatin: circumvention by use of a continu- ous infusional administration schedule,” Annals of Oncology, vol. 12, no. 11, pp. 1653–1654, 2001. [67] A. J. Newman Taylor, P. Cullinan, P. A. Lympany, J. M. Harris, R. J. Dowdeswell, and R. M. Du Bois, “Interaction of HLA